GlassScriptPhysician profile
Megan E Byram
NPI 1710428149
$5,388.09
in general payments reported to CMS, 2019-2025
21 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $337 · 2023: $1,877 · 2024: $1,595 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,050.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,336.01 | 2023-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $740.09 | 2022-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $711.52 | 2022-2025 | |
| Lilly USA, LLC | $470.77 | 2022-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $306.78 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $268.18 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.64 | 2023-2025 | Ofev, Cyltezo |
| Janssen Biotech, INC. | $232.93 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Horizon Therapeutics Plc | $166.29 | 2022-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $150.69 | 2023-2025 | Tyenne |
| Glaxosmithkline, LLC. | $132.56 | 2023-2025 | Benlysta, Nucala |
| Sandoz INC. | $111.46 | 2023-2025 | Hyrimoz |
| Radius Health, INC. | $107.56 | 2023-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $88.02 | 2023-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $66.25 | 2024-2025 | Orencia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $62.50 | 2023-2024 | |
| Sobi, INC | $59.71 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $58.43 | 2022-2023 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $29.21 | 2023 | |
| Organon LLC | $19.32 | 2024 | |
| Genzyme Corporation | $19.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Byram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.